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Background: Proton pump is an integral membrane protein that is ubiquitous ATP binding cassette (ABC) involved
in many transport processes in all living organisms, among which a specialized form of pump, so called p-type
proton pump, exists in the parietal cells of stomach. Though proton pump inhibitors (PPIs) are frequently prescribed
to prevent nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gastric damage, the acid suppressive actions do
not suffice to explain.
Methods: In order to document the effects of pantoprazole, one of PPIs, on the NSAIDs-induced gastric damage,
in vitro and in vivo studies were performed. Immunocytochemistry, Western blot analysis, electrophoretic mobility
shift assay and RT-PCR were conducted to evaluate the induction of heme oxygenase-1 (HO-1) through Nrf2
activation in normal gastric mucosal RGM-1 cells or in vivo stomach tissues from rats treated with indomethacin
and/or pantoprazole.
Results: Pantoprazole activated Nrf2 through inactivation of Keap1, after which the expression of HO-1 was
significantly increased in a dose-dependent manner in RGM-1 cells. Increased ARE-DNA binding activity was
observed maximally at 1 h with 300 μM of pantoprazole. The expression of HO-1 induced by pantoprazole was
significantly associated with the increased in vitro tube formation (P < 0.05) and angiogenic factors including VEGF,
bFGF, and HIF-1α. Indomethacin markedly increased the expressions of TNF-α, IL-1ß, IL-8, NOX-1, ICAM-1 and VCAM,
whereas pantoprazole significantly decreased the expressions of indomethacin-induced these inflammatory
mediators in accord with pantoprazole-induced HO-1 (P < 0.05) as documented with HO-1 inhibitor. In vivo model
of indomethacin-induced gastric damage could validate in vitro-drawn results that pantoprazole remarkably
protected against indomethacin-induced gastric damage, in which zinc protoporphyrin (5 mg/kg, ip) significantly
abolished the protective efficacy of pantoprazole.
Conclusion: These results demonstrate that Nrf2-mediated HO-1 induction of PPIs afforded a significant protective
effect against NSAIDs-induced gastric damage beyond acid suppressive actions.
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NSAIDs have huge prescription volumes mostly based
on the following two benefits, one is an increase of
aged patients necessitating NSAIDs prescription to re-
lieve degenerative change-induced pain and the other
is an additional trial for either the prevention of colon
polyps or the escape from ischemic cardiovascular dis-
eases [1,2]. However, the vast use of NSAIDs is limited
by troublesome adverse effects such as the gastric ero-
sion/ulcer, complicated bleeding from ulcers, and more
serious complications arising at the small intestine and
colon. Since the pharmacological action of NSAIDs is
through the inhibition of prostaglandin (PG) synthesis
via the suppression of cyclooxygenases (COX) [3], in-
discernible diminution of gastroprotective prostaglan-
din E2 (PGE2) is responsible for these gastrointestinal
(GI) adverse effects. Though the invention of selective
COX-2 inhibitor, coxib, to guarantee GI safety has
been suggested as the solving strategy, this solution
also needs to improve. Although NSAIDs are used as
potent anti-ulcer drugs, the additional uncovered
mechanisms of NSAID toxicity [4,5] lead us to develop
more potent and safer agents.
In the present time, the best choice for preventing
NSAIDs-related GI toxicity is either the combination of
NSAIDs and proton pump inhibitors (PPIs) or the
choice of coxibs [6,7]. Since the healing rate of GI ulcers
during continuous use of NSAIDs was greater in PPIs
group than histamine type 2 receptor antagonist (H2-
RA) group, PPIs have been preferred than H2-RA to
cope with the adverse effect of NSAIDs [8,9]. Besides
fundamental acid suppressive actions of PPIs, several
functions have been revealed which are the reduction of
pro-apoptotic signaling, acid-independent restoration of
proliferating and repairing pathways [10], a reduction in
mucosal oxidative damage, healing promoting action,
and endoplasmic reticulum stress relieving mechanism
[11-16]. Hahm et al. [17-19] have also reported that PPIs
show the potential activities as anticancer therapeutics
based on selective induction of apoptosis, anti-
angiogenesis against Helicobacter pylori-associated car-
cinogenesis, and direct anti-mutagenic actions during
tumorigenesis. However the mechanisms responsible for
the protective effects of PPIs in NSAIDs-induced gastric
damage remain to be determined.
Heme oxygenase-1 (HO-1), an inducible for the first
and rate-limiting enzyme of heme degradation, has been
known to protect against the cytotoxicity of oxidative
stress and apoptotic cell death as well as inflammatory
condition [20,21]. Fundamental protective effects of HO-1
against inflammation are mediated via anti-oxidative
heme degradation, but also associated with the produc-
tion of the anti-inflammatory mediators, for which redox
dependent transcriptional activator, NF-E2-related factor2 (Nrf2), and its phosphorylation/activation, and oxida-
tion of Kelch-like ECH-associating protein 1 (Keap1) is
mechanistically suggested [22-24]. Since the expres-
sion of HO-1 has been induced by anti-oxidative, anti-
inflammatory, and ischemic relieving responses, in the
current study, we hypothesized that the protective effects
of PPIs against NSAIDs-induced gastric damage may be
related to HO-1 and consequent angiogenesis beyond
innate acid suppression. Altogether, our results demon-
strate the novel mechanisms that PPIs induce the expres-
sion of HO-1 through activating Nrf2/inactivating Keap1
accompanied with the remuneration of ischemic change
and the attenuation of inflammatory mediators, thereby
facilitating protection against indomethacin-induced gas-
tric damage.
Methods
Materials and cell cultures
Indomethacin was purchased from Sigma Aldrich (Saint
Louis, MO) and pantoprazole was provided from Amore
Pacific Pharmaceutical Co. (Seoul, Korea). Antibodies
for β-actin, HO-1, α-tubulin, Keap1, Nrf2 and VEGF
were all obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Normal rat gastric mucosal RGM-1 cells
were provided by Prof. Hirofumi Matsui, MD, PhD (Tsu-
kuba Univ., Japan), were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% (v/v) fetal bo-
vine serum, 100 U/ml penicillin. Human umbilical vas-
cular endothelial cells (HUVECs) were cultured in M199
medium (InnoPharma Screen, Seoul, Korea). Cells were
maintained at 37°C in a humidified atmosphere contain-
ing 5% CO2. Appropriate amounts of RGM-1 cells or
HUVECs were seeded and incubated for 24 h, then they
were treated with the indicated dose of pantoprazole or
indomethacin and incubated for the indicated times.
HUVECs were moved to 1% O2 and 5% CO2 hypoxia
chamber and incubated for 0–12 h for the in vitro tube
formation assay.
Electron spin resonance (ESR) spectroscopy and ROS
generation measurement
Various concentrations of pantoprazole added to a total
volume of 200 μl containing 0.05 mM FeSO4, 1 mM
H2O2, 1 mM 5,5-dimethylpyrroline-N-oxide (DMPO,
Sigma Aldrich, Saint Louis, MO), and 50 mM sodium
phosphate at pH 7.4 at room temperature. Reactions
were initiated by adding H2O2. After incubation for 1
min, aliquots of the reactions were transferred to a
quartz cell and the spectrum of DMPO-OH was exam-
ined using an ESR spectrophotometer (JES-TE300,
JEOL, Tokyo, Japan) under the following conditions:
magnetic field, 338.0 ± 5.0 mT; microwave power, 4.95
mW; frequency, 9.421700 GHz; modulation amplitude, 5
mT; sweep time, 0.5 min; and time constant, 0.03 s.
Lee et al. BMC Gastroenterology 2012, 12:143 Page 3 of 11
http://www.biomedcentral.com/1471-230X/12/143Cellular ROS contents were measured by incubating the
control or pantoprazole treated RGM-1 cells with 10 μM
H2DCF-DA (Invitrogen Life Technologies, Carlsbad,
CA) for 30 min. Fluorescence was measured using a
confocal laser microscope (LSM710, Carl Zeiss, Oberko-
chen, Germany).
Western blot analysis
Treated cells were washed twice with PBS and then lysed
in ice-cold cell lysis buffer (Cell Signaling Technology)
containing 1 mM phenylmethylsulfonyl fluoride (PMSF,
Sigma Aldrich). Proteins in lysates were separated by
SDS-PAGE and transferred to polyvinylidene fluoride
(PVDF) membranes, which were incubated with primary
antibodies, washed, incubated with peroxidase-
conjugated secondary antibodies, rewashed, and then
visualized using an enhanced chemiluminescence (ECL)
system (GE Healthcare, Buckinghamshire, UK).
Electrophoretic mobility gel shift assay (EMSA)
Nuclear and cytoplasmic fractions were extracted using
NE-PER Nuclear and cytoplasmic reagents (Pierce,
Rockford, IL), according to the manufacturer’s instruc-
tions. Antioxidant response element (ARE) oligonucleotide
probe, 50-TTT TCT GCT GAG TCA AGG TCC G-30,
and HIF-1α oligonucleotide probe, 50-TCT GTA CGT
GAC CAC ACT CAC CTC-30, was labeled with [γ-32P]
ATP using T4 polynucleotide kinase (Promega, Madison,
WI) and separated from unincorporated [γ-32P] ATP by
gel filtration using a nick spin column (GE Healthcare).
Before adding the 32P-oligonucleotide (1x105 cpm), 10 μg
of nuclear extract was kept on ice for 15 min in gel shift
binding buffer. To determine the sequence specificity of
the NF-κB DNA interaction, we added an excess of un-
labeled oligonucleotides. After 20 min of incubation at
room temperature, 2 μl of 0.1% bromophenol blue was
added, and samples were electrophoresed through 6%
non-denaturing PAGE at 150 V in a cold room. Finally,
gels were dried and exposed to X-ray film (Kodak,
Rochester, NY).
Immunocytochemistry
Treated cells in chamber slides were fixed by 3.7% for-
maldehyde for 15 min. After washing, cells were
blocked in 5% BSA solution containing 0.1% Triton X-
100 in PBS for 1 h at room temperature, and then
incubated with primary antibody (1:100) for 12 h at
4°C. Cells were then washed 3 times, incubated with
secondary antibody (1:300) for 1 h, and then with 40-6-
diamidino-2-phenylindole (DAPI, 100 ng/ml) for 1 min
at room temperature. After washing 3 times, cells were
mounted with Prolong Gold antifade reagent (Invitro-
gen Life Technologies, Carlsbad, CA). Fluorescence wasvisualized under a confocal laser microscope (LSM710,
Carl Zeiss).
RNA isolation and quantitative reverse transcription
polymerase chain reaction (qRT-PCR)
After treatment, media was removed by suction and cells
were washed with Dulbecco’s phosphate-buffered saline
(DPBS) twice. RiboEX (Gene All, Seoul, Korea) was
added to plates, which were then incubated for 10 min
at 4°C. RiboEX was harvested and placed in a 1.5 ml
tube, and chloroform was added and gently mixed. After
incubation for 10 min in ice, samples were centrifuged
at 10,000 × g for 30 min. Supernatants were extracted
and mixed with isopropanol, and mixtures were incu-
bated at 4°C for 1 h. After centrifuging at 13,000 g for 30
min, pellet was washed with 70% (v/v) ethanol. After
allowing the ethanol to evaporate completely, pellets
were dissolved in diethylene pyrocarbonate (DEPC)-trea-
ted water (Invitrogen Life Technologies, Carlsbad, CA).
cDNA was prepared using reverse transcriptase derived
from murine Maloney leukemia virus (Promega, Madi-
son, WI), according to the manufacturer’s instructions.
PCR was performed over 30 cycles of: 94°C for 20 sec,
58°C for 30 sec, and 72°C for 45 sec. Oligonucleotide
primers for PCR (Table 1) were purchased from Bioneer
(Daejeon, Korea). All qRT-PCR experiments were
repeated in triplicate and quantification was shown in
mean ± SD.
In vitro angiogenesis assay
This assay was performed using a commercial kit
according to the manufacturer’s instruction (Millipore,
Billerica, MA). For hypoxic conditions, ECMatrix and
Diluent buffer were mixed to make a solid gel, which
was then plated in 96 well microplates. Human umbilical
vein endothelial cells (HUVEC, 1.0 × 105/ml) were
seeded with control, Indomethacin, indomethacin plus
pantoprazole, indomethacin plus pantoprazole plus
ZnPPIX incubated at 37°C for 4 h. Tube formation was
observed under a light microscope.
Indomethacin-induced gastric damage model
A total of 48 rats were purchased from Charles River
(Osaka, Japan). Animals were handled in an accredited
animal facility in accordance with Association for As-
sessment and Accreditation of Laboratory Animal Care
International (AAALAC International) guidelines under
the facility named CACU (The Center of Animal Care
and Use) of Lee Gil Ya Cancer and Diabetes Institute,
Gachon University after Institutional Ethics Review
Board approval. Animals were divided into four groups
each consisting of 12 rats and were starved for 24 h be-
fore the experimentation as follows; all rats were admi-
nistered with intraperitoneal injection of indomethacin
Table 1 The sequence of PCR primers
GAPDH Forward 50-GGT GCT GAG TAT GTC GTG GA -30
Reverse 50-TTC AGC TCT GGG ATG ACC TT-30
HO-1 Forward 50-GAG AGC ATG TCC CAG GAT TT-30
Reverse 50-GGT TCT GCT TGT TTC GCT CT -30
COX-2 Forward 50-GAA ATG GCT GCA GAG TTG AA -30
Reverse 50-TCA TCT AGT CTG GAG TGG GA -30
HIF-1α Forward 50-AAC AAA CAG AAT CTG TCC TC-30
Reverse 50-GGT AAT GGA GAC ATT GCC AG-30
VEGF Forward 50-CAA TGA TGA AGC CCT GGA GT-30
Reverse 50-GAT TTC TTG CGC TTT CGT TT -30
PDGF Forward 50-AGG AAG CCA TTC CCG CAG TT-30
Reverse 50-CTA ACC TCA CCT GGA CCT CT -30
bFGF Forward 50-TAT GAA GGA AGA TGG ACG GC-30
Reverse 50-AAC AGT ATG GCC TTC TGT CC -30
IL-1β Forward 50-CAT TGT GGC TGT GGA GAA G-30
Reverse 50-ATC ATC CCA CGA GTC ACA GA -30
IL-8 Forward 50-CAG ACA GTG GCA GGG ATT CA-30
Reverse 50-TTG GGG ACA CCC TTT AGC AT-30
TNF-α Forward 50-TAC TGA ACT TCG GGG TGA TT -30
Reverse 50-CAG CCT TCT CCC TTG AAG AG-30
ICAM-1 Forward 50-TGT GCT TTG AGA ACT GTG GC-30
Reverse 50-GGT TCT GTC CAA CTT CTC AG -30
VCAM-1 Forward 50-GAG ACA AAA CAG AAG TGG AAT-30
Reverse 50-TAC AAG TGG TCC ACT TAT TTC -30
NOX1 Forward 50-GAG AAA TTC TCG GAA CTG CC-30
Reverse 50-TGT TGG CTT CTA CTG TAG CG -30
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with intraperitoneal injection of 10 mg/kg of pantopra-
zole, the third group with intraperitoneal injection of 30
mg/kg of pantoprazole, and the fourth group with intra-
peritoneal injection of 30 mg/kg of pantoprazole and 5
mg/kg of ZnPPIX to inhibit the activity of HO-1. Ani-
mals were sacrificed 16 h after each administration. The
stomachs of rats were removed and opened along the
greater curvature and then washed with ice cold phos-
phate buffered solutions. The numbers of either erosions
or ulcers were determined under the magnified photo-
graphs. Homogenates obtained from scratched gastric
mucosa were kept into liquid nitrogen tank until the
assay.Statistical analysis
Results are expressed as the mean ± SD. The data were
analyzed by one-way ANOVA, and the statistical signifi-
cance between groups was determined by Duncan’smultiple range test. Statistical significance was accepted
at P < 0.05.
Results
Pantoprazole increased HO-1 expression through Nrf2
activation
Based on preliminary study, we have found pantoprazole
showed the highest induction of HO-1 expression in
RGM-1 cells among PPIs, lansoprazole, rabeprazole,
omeprazole, and pantoprazole (data not shown). Panto-
prazole increased the expression of HO-1 mRNA and
protein in a dose-dependent manner (Figure 1A) and
immunocytochemical analysis also revealed that the level
of HO-1 was significantly increased by pantoprazole
treatment in the cytoplasm of RGM-1 cells in a dose-
dependent manner (Figure 1B). To understand the
mechanisms underlying the up-regulation of HO-1 ex-
pression by pantoprazole, we examined its effects on the
activation of Nrf2, a major transcription factor that med-
iates the ARE/EpRE-driven expression of antioxidant
enzymes. When we measured the expression level of
keap1, a repressor of Nrf2 in cytoplasmic fraction trea-
ted with 300 μM pantoprazole in a different time point,
significantly decreased expression of Keap1 was
observed in 1 h (Figure 2A), suggesting that HO-1 might
be transcribed after pantoprazole treatment through
Nrf2 activation and Keap1 inactivation. As illustrated in
Figure 2A, Nrf2 nuclear co-localization was evident in
RGM-1 cells treated with pantoprazole. The maximum
ARE-binding activity of Nrf2 was increased in 1 h as
well as its nuclear localization induced by pantoprazole
(Figure 2B). To ascertain the nuclear accumulation of
Nrf2, we conducted an immunocytochemical analysis
using the anti-Nrf2 antibody. As shown in Figure 2C,
Nrf2 was translocated into nucleus with 300 μM panto-
prazole treatment. These results consistently suggested
that pantoprazole could increase HO-1 levels through
transcriptional activation of Nrf2 in rat gastric epithelial
cells.
Since the biological significance of HO-1 pantoprazole
possesses an anti-oxidative action related to HO-1 in-
duction. ESR measurement was ultimate way to trace
free radical generation using spin adduct, for which we
generated hydroxyl radicals using DMPO as an adductor
under Fenton reaction. As seen in Figure 2D, 3 mM
pantoprazole exerted clear scavenging action of DMPO-
adduct-generating hydroxyl radicals. Since ESR measure-
ment was executed in chemical reaction condition not
biological system and pantoprazole is not a professional
antioxidant, it definitely contributed to scavenge hy-
droxyl radicals even though it is relatively high concentra-
tion of pantoprazole to scavenge reactive oxygen species.
These chemical results from ESR study were further vali-
















































































Figure 1 Pantoprazole induced the expression of HO-1. (A) RT-PCR and Western blot for HO-1 expression according to different dosing of
pantoprazole, 30, 100, and 300 μM, respectively. These figures are representatives of the results obtained in 3 independent experiments. (B)
Confocal imaging of HO-1. Pantoprazole increased the expression of HO-1 in a dose-dependent manner in normal rat gastric mucosal RGM-1
cells.
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cant DCF-DA reduction in a dose-dependent manner (P
< 0.05, Figure 2E).
Angiogenic actions consequent to pantoprazole-induced
HO-1
PPIs increased the expressions of VEGF mRNA and pro-
tein in RGM-1 cells (Figure 3A). In order to document
whether the incremental induction of VEGF with PPIs is
related to HO-1 induction, we repeated the experiments
with PPI alone or co-treatment of pantoprazole and zinc
protoporphyrin (ZnPPIX) as HO-1 inhibitor. As results,
we could reconfirm the expression of VEGF induced by
pantoprazole and incremental co-treatment of ZnPPIX
clearly decreased the expression of PPI-induced VEGF
in a dose-dependent manner (Figure 3B). Next, we
investigated the changes of representative angiogenic
factors, bFGF, PDGF, and HIF-1α and observed theseexpressions relevant to pantoprazole-induced HO-1 in
Figure 3C. As anticipated, pantoprazole significantly
increased these expressions of several angiogenic factors.
Also these inductions of bFGF and PDGF were signifi-
cantly attenuated with co-treatment of pantoprazole and
ZnPPIX. In order to verify whether these inductions of
angiogenic factor after pantoprazole were actually
related to angiogenesis, in vitro angiogenesis assay was
done (Figure 3D). Tube formation was significantly atte-
nuated with 500 μM indomethacin in HUVECs, whereas
100 μM pantoprazole could overcome these derange-
ments of angiogenesis treated with indomethacin. How-
ever, additional treatment with ZnPPIX abolished these
benefits of overcoming angiogenesis by pantoprazole
under indomethacin administration. These results sug-
gest that pantoprazole compensated NSAIDs-induced
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Figure 2 Pantoprazole increased Nrf2 nuclear translocation and cytoplasmic keap1 inactivation, led to significant anti-oxidation. (A)
Western blots for either cytosolic Keap1 or nuclear Nrf2 in a different time in the presence of 300 μM pantoprazole. (B) Electrophoretic mobility
shift assay (EMSA) for ARE-DNA binding activity. Significantly increased DNA-binding of Nrf2 was noted 60 min after pantoprazole administration.
(C) Confocal imaging of Nrf2 after different dosing of pantoprazole, 100 μM and 300 μM. (D) Electron spin resonance (ESR) measurement for
Fenton reaction-generated hydroxyl radicals. (E) The changes of DCF-DA fluorescence after different dosing of pantoprazole, 30, 100, and 300 μM.
Pantoprazole decreased significantly H2O2-induced oxidative fluorescence.
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associated inflammatory assault
Though indomethacin is an anti-inflammatory agent, it
has been known that NSAIDs induced gastric damage
through increased expressions of inflammatory media-
tors including TNF-α, IL-1β, IL-8, and NADPH oxidase-
1 (NOX-1). As seen in Figure 4A, 500 μM indomethacin
significantly increased the expressions of TNF-α, IL-1β,
and IL-8 in gastric epithelial cells, whereas it decreased
the expression of HO-1, confirming that inflammatory
mediators might be mechanistically associated with
indomethacin-induced gastric epithelial cell damage. In
this condition, co-administration of 500 μM indometh-
acin and 300 μM pantoprazole significantly decreased
the expressions of TNF-α, IL-1β, and IL-8 accompanied
with statistically significant increases of HO-1 expres-
sion. Additionally, indomethacin challenge significantly
increased the expressions of NOX-1, in whichpantoprazole significantly attenuated the increased ex-
pression of NOX-1, suggesting that pantoprazole-
induced HO-1 imposed anti-inflammatory actions under
indomethacin. Next, in order to further prove whether
these attenuations of inflammatory mediators after pan-
toprazole are resulted from HO-1 induction, we repeated
these experiments with ZnPPIX administration. As seen
in Figure 4B, the co-treatment of ZnPPIX in the pres-
ence of pantoprazole significantly abolished the benefits
of anti-inflammatory action. The incremental inductions
of ICAM-1 and VCAM after indomethacin treatment
were responsible for ischemia and aggravated organ
damages, in which either vascular inflammation or
increased leukocyte aggregation was engaged. Treatment
with indomethacin significantly increased the expres-
sions of ICAM-1 and VCAM in HUVEC, but co-
challenge of indomethacin and pantoprazole significantly
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Figure 3 Pantoprazole induced angiogenic factors related to HO-1 induction. (A) RT-PCR and western blot for VEGF. Significant inductions
of VEGF were noted with pantoprazole, significantly after 300 μM pantoprazole (p<0.05). These figures are representatives of the results obtained
in 3 independent experiments. (B) The changes of VEGF and HO-1 with pantoprazole alone or combination of pantoprazole and ZnPPIX. The
induction of VEGF after pantoprazole was significantly attenuated with HO-1 inhibitor, signifying the implication of HO-1 in PPI-induced VEGF.
These figures are representatives of the results obtained in 3 independent experiments. (C) Other angiogenic factors related to pantoprazole.
bFGF and VEGF was increasingly expressed with pantoprazole, but these inductions were attenuated with HO-1 inhibitor. These figures are
representatives of the results obtained in 3 independent experiments. (D) in vitro angiogenesis assay. Tube formation of HUVEC was significantly
decreased with 50 μM indomethacin. Pantoprazole compensated indomethacin-induced defective angiogenesis as assessed with the percentage
of tube formation, whereas HO-1 inhibitor cancelled these overcome of pantoprazole-induced angiogenesis. These figures are representatives of
the results obtained in 3 independent experiments.
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this condition, ZnPPIX did not impose the attenuation
of ICAM or VCAM in spite of pantoprazole treatment,
further assuring the beneficiary action of pantoprazole
associated with HO-1 induction.
Pantoprazole-induced HO-1 enfeebled indomethacin-
induced gastric injury
To investigate the protective effect of pantoprazole
in vivo, indomethacin (10 mg/kg) was administered
intraperitoneally for 16 h in rats. Treatment with indo-
methacin significantly provoked gastric mucosal injuries
including hemorrhagic erosions and ulcerations.
However, these gastric pathologies provoked withindomethacin were significantly attenuated with
intraperitoneal injection of 30 mg/kg pantoprazole
(Figure 5A). Since these protective effects of 30 mg/kg
pantoprazole against indomethacin-induced gastric
damages were significantly abolished with co-treatment
of intraperitoneal administered 5 mg/kg ZnPPIX, we
confirmed that the protective action of pantoprazole was
based on its capability of HO-1 induction. When the
expressions of HO-1 and ICAM-1 were measured in
mucosal homogenates from each group, indomethacin
administration significantly decreased the expressions of
HO-1 and increased the expression of ICAM-1. How-
ever, owing to increased HO-1 expressions after panto-
prazole as well as significantly attenuated levels of
GAPDH
HO-1
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Figure 4 Pantoprazole attenuated indomethacin-induced inflammatory mediators through HO-1. (A) RT-PCR for TNF-α, IL-1β, IL-8, and
HO-1. 500 μM indomethacin increased the expression of inflammatory mediators including TNF-α, IL-1β, IL-8, but significantly decreased HO-1
expression. NOX-1 was significantly increased with indomethacin. These figures are representatives of the results obtained in 3 independent
experiments. (B) Pantoprazole significantly decreased indomethacin-induced IL-1β and TNF-α, but these beneficiary actions of pantoprazole were
abolished with ZnPPIX, leading to the conclusion that anti-inflammatory actions of pantoprazole were owing to HO-1 induction. These figures are
representatives of the results obtained in 3 independent experiments. (C) Pantoprazole significantly decreased indomethacin-induced ICAM-1 and
VCAM in HUVEC cells, but these beneficiary actions of pantoprazole were also abolished with ZnPPIX as HO-1 inhibitor. These figures are
representatives of the results obtained in 3 independent experiments.
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proportionally improved in spite of indomethacin chal-
lenge (Figure 5B). To demonstrate how pantoprazole
improved the defective angiogenesis and ischemia pro-
voked by indomethacin, EMSA using HIF-1α was per-
formed (Figure 5C). The HIF-1α-DNA binding activity
was highly increased in indomethacin alone group,
which was significantly decreased in gastric homoge-
nates of pantoprazole treatment group, signifying pan-
toprazole significantly relieved hypoxic condition
induced by indomethacin. Taken together, PPIs exerted
strong protection against indomethacin-induced gastric
mucosal damage through significant HO-1 induction,
which is beyond authentic acid suppressive action,
though we did not measure the changes of gastric
acidity.Discussion
Before the current investigation, several researchers have
published that PPIs could prevent gastric mucosal injury
by other mechanisms beyond the action of its specific
acid inhibition [11,14,25-28], we could add more evi-
dences regarding protective action of PPIs against
NSAIDs. Pantoprazole significantly induced the expres-
sion of HO-1 through Nrf2 activation relevant to anti-
inflammatory, anti-oxidative, and ischemia relieving
actions. Novel finding of this study different from other
investigations is that pantoprazole shows protective
actions to the NSAIDs-induced injury through either the
correction of angiogenic handicap or the attenuation of
inflammation propensity.
Becker JC et al. [16] demonstrated that both omepra-
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Figure 5 Pantoprazole prevents to the indomethacin-induced gastric damage through depending on the induction of HO-1. (A) Mean
index of indomethacin-induced gastric damages. (B) RT-PCR for HO-1 and ICAM-1 according to group. (C) EMSA for HIF-1α according to group.
Indomethacin significantly increased HIF-1α-DNA binding, whereas pantoprazole significantly decreased HIF-1α-DNA binding in a dose-
dependent manner.
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our study, but used different kinds of PPIs. Since this ef-
fect was abrogated in the presence of the HO-1 inhibi-
tor, ZnPPIX, HO-1 seems to be a right target of PPIs in
both endothelial and gastric epithelial cells. In this study,
we observed untouched novel finding that HO-1
induced by PPIs decreased NSAIDs-incurred inflamma-
tion and angiogenic derangement. Takagi T et al. [25]
also investigated the role of Nrf2, its phosphorylation/ac-
tivation, and oxidation of Keap1 in lansoprazole-induced
HO-1 up-regulation using same cell line with us, RGM-
1 cells. When RGM-1 cells were transfected with HO-1
enhancer luciferase reporter plasmid containing mutant
stress response element, lansoprazole-induced HO-1 re-
porter gene activity was not increased. Taken together
with our results, lansoprazole or pantoprazole up-regulated HO-1 expression and this up-regulated HO-1
contributed to the anti-inflammatory effects. Against
gastric damage induced by NSAIDs, PPIs significantly
reduced the mRNA expression and production of TNF-
α and IL-1β in THP-1 cells stimulated by other irritants
such as lipopolysaccharide (LPS) and H. pylori water
extracts [15]. Lansoprazole inhibited the phosphoryl-
ation and degradation of inhibitory factor kappaB-alpha
(IκBα) and phosphorylation of ERK in THP-1 cells,
reaching to the conclusion that PPIs could exert anti-
inflammatory effects by directly suppressing induction of
TNF-α and IL-1β via the inhibition of NF-κB and ERK
activation in inflammatory cells. Though they used in-
flammatory cells and we used gastric mucosal cells, we
observed similar results that PPIs-induced HO-1 signifi-
cantly inhibited indomethacin-induced levels of TNF-α
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treatment with 90 μM/kg lansoprazole significantly pre-
vented alcohol-induced gastric damage, suggesting a
significant reduction of gastric oxidative stress associated
with an increased bioavailability of mucosal sulfhydryl
(SH) compounds.
Then, the question arises whether there might be dif-
ference in PPIs-induced protective mechanisms accord-
ing to kinds of NSAIDs or kinds of PPIs. Blandizzi C
et al. [29] treated male Sprague–Dawley rats with several
kinds of NSAIDs, 100 μM/kg indomethacin, 60 μM/kg
diclofenac, 150 μM/kg piroxicam or 150 μM/kg ketopro-
fen. Thirty minutes before NSAIDs, animals were orally
treated with lansoprazole and four hours after the end of
treatment, gastric mucosal PGE2, malondialdehyde
(MDA), myeloperoxidase (MPO) or non-protein sulfhy-
dryl compounds (GSH) levels were measured, respect-
ively. As result, PPIs prevented against NSAIDs-induced
gastric damage irrespective of kinds of NSAIDs, mainly
alleviating NSAIDs-induced mucosal oxidative injury
[28]. In preliminary study, we have also tested the HO-1
inducing capacity according to PPIs including lansopra-
zole, pantoprazole, rabeprazole, and omeprazole and we
have found pantoprazole was the best in inducing HO-1
as well as other biological actions. We speculated these
differences were based on the stability of PPI in aqueous
condition.
Interestingly, these protective actions of PPIs against
NSAIDs-induced gastric damages were not confined to
just stomach. According to Takagi T et al. [27], they
investigated whether PPIs ameliorated intestinal mucosal
injuries induced by ischemia-reperfusion in rats and
found that lansoprazole or pantoprazole have been
demonstrated to prevent gastrointestinal mucosal injury
by mechanisms independent of acid inhibition. Esome-
prazole also counteracted the detrimental action of indo-
methacin on ulcer repair through both acid-dependent
and acid-independent mechanisms [26]. Though subtle
difference in the action mechanisms related to acid sup-
pression, PPIs irrespective of kinds were similar in the
protective action beyond acid suppression, but we have
used pantoprazole in our investigation, which shows ut-
most protective actions against NSAIDs-induced gastric
damages based on HO-1 induction.
Conclusion
We confirmed the new finding, never touched before,
how pantoprazole can protect stomach from NSAIDs-
induced gastric damage beyond authentic acid suppressive
action and elucidated the mechanism that pantoprazole
improved NSAIDs-induced ischemia and attenuated
NSAIDs-associated gastric inflammation through Nrf2-
driven HO-1 induction. Conclusively, PPIs in the current
form or newer formulation based on reinforced action ofPPIs-induced HO-1 expression will cover NSAIDs-
induced gastric damage. However, more investigations
will be prerequisite whether this kind of protection with
PPIs can also be ascribed to NSAIDs-induced enterop-
athy although there were conflicting reports, that is, one
study showed PPIs can aggravate NSAIDs-induced enter-
opathy through dysbiosis [30], but other study showed
prevention by lansoprazole of indomethacin-induced
small intestinal ulceration in rats through induction of
HO-1 and carbon monoxide [31].
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